Adverum Biotechnologies, Inc.
NASDAQ:ADVM
Overview | Financials
Company Name | Adverum Biotechnologies, Inc. |
Symbol | ADVM |
Currency | USD |
Price | 4.74 |
Market Cap | 98,603,850 |
Dividend Yield | 0% |
52-week-range | 4.59 - 29.7 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Laurent Fischer |
Website | https://www.adverum.com |
An error occurred while fetching data.
About Adverum Biotechnologies, Inc.
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema.
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD